Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027

As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million

Torqur taps Lonza to power late-stage push for skin cancer therapy

Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds

Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients

The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks

Wockhardt’s breakthrough antibiotic Zaynich wins key regulatory nod in India

Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal

Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones

MGM Healthcare builds world’s largest intestinal transplant program in 3 years

Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone

Merck strikes $6.7 billion deal to acquire terns, bolstering cancer pipeline

TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances

New diabetes drug UBT251 shows strong phase 2 results in China

Godavari Biorefineries secures Japanese patent for antiviral compounds

The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways

Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026

Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses